Double Recognition: Smart Communications Named a Leader in IDC MarketScape Reports for Intelligent CCM and Automated Document Generation
Smart Communications™, a leading technology company focused on transforming customer conversations, announced today that it has been named a ‘Leader’ in the IDC MarketScape: Worldwide Intelligent Customer Communications Management 2024 Vendor Assessment (doc # US51359124, December 2024). Additionally, the company was recognized as a Leader in the IDC MarketScape: Automated Document Generation and Customer Communications Management 2024 Vendor Assessment (doc # US52111324, December 2024).
The IDC MarketScape: Intelligent Customer Communications Management report represents the industry’s evolution toward digital-first, AI-powered solutions that enable organizations to streamline customer interactions, drive personalization and adapt to the growing complexity of data collection and communications across multiple channels.
“We believe being named a Leader in the IDC MarketScape: Intelligent Customer Communications Management report reflects the industry’s transformation and the growing importance of AI-driven customer communications and intelligent forms,” said Leigh Segall, CEO of Smart Communications. “Additionally, we’re proud to be a Leader in the IDC MarketScape: Automated Document Generation and Customer Communications Management report. Our focus remains on delivering solutions that address today’s needs while paving the way for the future of customer conversations.”
The reports noted key strengths for Smart Communications such as:
- According to the IDC MarketScape for Intelligent Customer Communications, “Smart Communications offers a combined intelligent AI-based forms and communications platform with a single access point to generate all communications from forms to batch, interactive or on-demand, while maintaining security standards for regulated documents and an accessibility panel for output and UI improvements.”
- According to the IDC MarketScape for Intelligent Customer Communications, “Smart Communications provides augmented template design and authoring assistant features such as translation and content intelligence dashboard for readability and sentiment. GenAI native capabilities within the product can block content from training external models.”
- According to the IDC MarketScape for Intelligent Customer Communications, "Smart Communications rewrote its cloud services to improve communication processing times and API calls at high speed with reusable content blocks served by a strong microservices architecture that allows for easier integration to various applications and connects interactive communications to its forms technology.”
“We believe these reports validate our commitment to providing innovative solutions that drive real business impact,” said Simon Tindal, CTO of Smart Communications. “Our platform’s advanced capabilities, from AI-powered tools to seamless integrations, enable organizations to meet evolving customer expectations while achieving operational efficiency and scalability.”
Smart Communications’ cloud-based flagship offerings include:
- SmartIQ™ – A low-code process automation solution that transforms traditional forms-based workflows into fast, guided digital experiences.
- SmartCOMM™ – A next-generation CCM solution delivering personalized, interactive communications across all channels at scale.
These solutions power The Conversation Cloud™, an end-to-end platform enabling fully digital customer conversations with secure data collection, workflow automation, collaboration, and centralized management of customer conversations across all channels.
Explore the IDC MarketScape excerpts here.
About IDC MarketScape:
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
About Smart Communications:
Smart Communications provides the platform that leading organizations trust to deliver personalized, consistent and compliant conversations across all touchpoints and channels. The Conversation Cloud™ consists of SmartCOMM™, for enterprise-scale customer communications, SmartIQ™ for digital forms transformation and SmartDX™ for trade documentation. Over 650 enterprise organizations across the globe rely on Smart Communications to simplify and automate complex processes and deliver highly secure, frictionless experiences across the customer lifecycle. To learn more, visit smartcommunications.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205075495/en/
Contacts
Media:
Smartcommunications@rlyl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom